JP2013521231A - ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する - Google Patents

ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する Download PDF

Info

Publication number
JP2013521231A
JP2013521231A JP2012555195A JP2012555195A JP2013521231A JP 2013521231 A JP2013521231 A JP 2013521231A JP 2012555195 A JP2012555195 A JP 2012555195A JP 2012555195 A JP2012555195 A JP 2012555195A JP 2013521231 A JP2013521231 A JP 2013521231A
Authority
JP
Japan
Prior art keywords
peptide
muscle
induced
diaphragm
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012555195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521231A5 (enExample
Inventor
ヘーゼル エイチ ツェト
スコット クライン パワーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of JP2013521231A publication Critical patent/JP2013521231A/ja
Publication of JP2013521231A5 publication Critical patent/JP2013521231A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2012555195A 2010-02-26 2011-02-25 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する Pending JP2013521231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30850810P 2010-02-26 2010-02-26
US61/308,508 2010-02-26
PCT/US2011/026339 WO2011106717A1 (en) 2010-02-26 2011-02-25 Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016110116A Division JP2016164194A (ja) 2010-02-26 2016-06-01 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する

Publications (2)

Publication Number Publication Date
JP2013521231A true JP2013521231A (ja) 2013-06-10
JP2013521231A5 JP2013521231A5 (enExample) 2014-04-17

Family

ID=44507242

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012555195A Pending JP2013521231A (ja) 2010-02-26 2011-02-25 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2016110116A Pending JP2016164194A (ja) 2010-02-26 2016-06-01 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2017182579A Pending JP2017226699A (ja) 2010-02-26 2017-09-22 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2018242635A Pending JP2019069985A (ja) 2010-02-26 2018-12-26 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016110116A Pending JP2016164194A (ja) 2010-02-26 2016-06-01 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2017182579A Pending JP2017226699A (ja) 2010-02-26 2017-09-22 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
JP2018242635A Pending JP2019069985A (ja) 2010-02-26 2018-12-26 ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する

Country Status (6)

Country Link
US (6) US20130040901A1 (enExample)
EP (4) EP3167896A1 (enExample)
JP (4) JP2013521231A (enExample)
CN (2) CN102834105A (enExample)
CA (1) CA2790823A1 (enExample)
WO (1) WO2011106717A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522311A (ja) * 2010-03-15 2013-06-13 ステルス ペプチドズ インターナショナル インコーポレイテッド シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法
JP2019147815A (ja) * 2013-03-01 2019-09-05 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US11312993B2 (en) 2013-06-26 2022-04-26 Stealth Biotherapeutics Inc. Methods and compositions for detecting and diagnosing diseases and conditions

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150215A1 (en) 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3170506B1 (en) 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
MX2015005102A (es) * 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
EP3182989B1 (en) * 2014-08-21 2021-04-14 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
WO2016144968A1 (en) * 2015-03-09 2016-09-15 University Of Washington Relaxin therapy for disorders of the diaphragm
EP4233887A1 (en) * 2016-01-06 2023-08-30 Stealth BioTherapeutics Inc. Methods for the treatment of duchenne muscular dystrophy
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
EP4000690A1 (en) * 2016-05-19 2022-05-25 Stealth BioTherapeutics Inc. Compositions and methods for the prevention and treatment of mitochondrial myopathies
US10398732B2 (en) 2016-10-13 2019-09-03 Marshall University Research Corporation Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth
KR101986882B1 (ko) * 2017-01-06 2019-06-07 연세대학교 산학협력단 오시멘, 유게놀 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
JP2019099488A (ja) * 2017-11-30 2019-06-24 小林製薬株式会社 ペプチド及びその利用
WO2022055811A1 (en) * 2020-09-09 2022-03-17 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
CN115400201A (zh) * 2021-05-26 2022-11-29 四川大学华西医院 Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114870000B (zh) * 2022-03-21 2025-10-28 中国人民解放军空军军医大学 用于线粒体靶向治疗的两亲性前药及其纳米颗粒的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6015006641; Ｆｒｅｅ　Ｒａｄｉｃａｌ　Ｂｉｏｌｏｇｙ　＆　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．４６，Ｎｏ．６, 2009, ｐ８４２-８５０ *
JPN6015006643; Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｐｈｙｓｉｏｌｏｇｙ Ｖｏｌ．９５，Ｎｏ．１, 201001, ｐ１-９ *
JPN6015006644; Ａｍｅｒｉｃａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｒｅｓｐｉｒａｔｏｒｙ　ａｎｄ　Ｃｒｉｔｉｃａｌ　Ｃａｒｅ Ｖｏｌ．１７０，Ｎｏ．１１, 2004, ｐ１１７９-１１８４ *
JPN6015006646; Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈｙｓｉｏｌｏｇｙ Ｖｏｌ．５８５，Ｎｏ．１, 2007, ｐ２０３-２１５ *
JPN6015006648; ＡＡＰＳ　Ｊｏｕｒｎａｌ Ｖｏｌ．８，Ｎｏ．２, 2006, ｐＥ２７７-Ｅ２８３ *
JPN6015006650; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２７９，Ｎｏ．３３, 2004, ｐ３４６８２-３４６９０ *
JPN6015006652; Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．９８，Ｎｏ．４, 2006, ｐ１１４１-１１４８ *
JPN6016003126; 日本栄養・食糧学会総会講演要旨集 , 2006, ｐ２８８ *
JPN6016003128; Ｊｏｕｒｎａｌ　ｏｆ　Ａｐｐｌｉｅｄ　Ｐｈｙｓｉｏｌｏｇｙ Ｖｏｌ．１０２，Ｎｏ．３, 2007, ｐ１１４３-１１５１ *
JPN6016003130; Ａｍｅｒｉｃａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈｙｓｉｏｌｏｇｙ．　Ｒｅｇｕｌａｔｏｒｙ，　Ｉｎｔｅｇｒ Ｖｏｌ．２９３，Ｎｏ．３, 2007, ｐＲ１１５９-Ｒ１１６８ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522311A (ja) * 2010-03-15 2013-06-13 ステルス ペプチドズ インターナショナル インコーポレイテッド シクロスポリンおよび芳香族カチオン性ペプチドを用いた併用療法
US11771734B2 (en) 2013-03-01 2023-10-03 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
JP2021098704A (ja) * 2013-03-01 2021-07-01 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
US11083771B2 (en) 2013-03-01 2021-08-10 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of Barth Syndrome
US11083772B2 (en) 2013-03-01 2021-08-10 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of Barth Syndrome
JP7072692B2 (ja) 2013-03-01 2022-05-20 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
JP2022116008A (ja) * 2013-03-01 2022-08-09 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
JP2019147815A (ja) * 2013-03-01 2019-09-05 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
JP7381652B2 (ja) 2013-03-01 2023-11-15 ステルス バイオセラピューティクス インコーポレイテッド バース症候群の予防または治療のための方法及び組成物
US12268724B2 (en) 2013-03-01 2025-04-08 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth Syndrome
US11312993B2 (en) 2013-06-26 2022-04-26 Stealth Biotherapeutics Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US12297502B2 (en) 2013-06-26 2025-05-13 Stealth Biotherapeutics Inc. Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
CN104922653A (zh) 2015-09-23
JP2016164194A (ja) 2016-09-08
EP3511012A1 (en) 2019-07-17
US20230076067A1 (en) 2023-03-09
EP2538958A1 (en) 2013-01-02
US20200282003A1 (en) 2020-09-10
US20130040901A1 (en) 2013-02-14
EP3332795A1 (en) 2018-06-13
US20180311301A1 (en) 2018-11-01
CA2790823A1 (en) 2011-09-01
CN102834105A (zh) 2012-12-19
US20170143784A1 (en) 2017-05-25
EP3167896A1 (en) 2017-05-17
US20160058826A1 (en) 2016-03-03
JP2017226699A (ja) 2017-12-28
WO2011106717A1 (en) 2011-09-01
JP2019069985A (ja) 2019-05-09
EP2538958A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
US20230076067A1 (en) Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
US12102659B2 (en) Methods for the prevention or treatment of heart failure
DK2464371T3 (en) Methods for preventing or treating metabolic syndrome
CA2920020C (en) Methods and compositions for the prevention and treatment of friedreich's ataxia
JP2019052158A (ja) カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する
WO2016004441A1 (en) Methods for the prevention or treatment of acute myocardial infarction injury
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160201